Similarly, treating WKO B cells with the N-WASP inhibitor wiskostatin (Figure 2D) [51] or A20 lymphoma B cells with siRNAs targeted to WASP and N-WASP (Figure 2B,F) reduced the BCR TFI in the contact zone to levels similar to that in cDKO B cells. The gene discussed is BCR; the disease is lymphoma.